Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03269669
Title Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Recruitment Suspended
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

follicular lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Obinutuzumab + Prednisone + Vincristine Sulfate

Lenalidomide + Obinutuzumab

Obinutuzumab + Umbralisib

Prednisone

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.